【摘要】 本文报告广州、上海及北京三家癌症中心对异环磷酰胺进行Ⅱ期临床试验的结果。27例非何杰金氏淋巴瘤中,14例未经治疗的新病例单用异环磷酰胺治疗,总缓解率57％（其中1例CR）。13例经第一线治疗失败的淋巴瘤,试用异环磷酰胺联合化疗（IMVP—16）,结果CR3例,PR4例,总缓解率54％。9例未经治疗的小细胞肺癌单用异环磷酰胺治疗,6例（67％）获PR,16例初治失败的小细胞肺癌改用异环磷酰胺—VP₁₆治疗,5例CR,9例PR,总缓解率87％。异环磷酰胺主要毒性反应为骨髓抑制,恶心呕吐及脱发,多为Ⅰ至Ⅱ度,停药后易恢复,并用Mesna仅偶见发生血尿者。更多还原

【Abstract】 Phase n clinical study of 27 cases of median and high grade non-hodg-gkin’s lymphomas (14 previously untreated and 13 previously treated) and 25 cases of small cell, lung cancer ( 9previonusly untreated and 16 treated) were carried out in 3 cancer centers. The previously untreated cases (both NHL and SCLC) were treated with ifosfamide/ mesna single drug however, in 13 cases of NHL who failed first line chemotherapy (mainly CHOP), patients were treated with IWVP-16 and in 16 cases of treated SCLC, patients were treated with IFO-VP-16.The results showed that single drug IFO/MESNA was quite responsive in previously untr-trested NHL and sclc, with response rate 57% and 67 respectively. IMvp-16 used as a salvage treatment in NHL achieved 23% CR and 54% overall response rate, and IFO-VP-16 achie-eved 31%CR and 87% overall response rate in SCLC failed first line treatment. The main to-xicities was marrow suppresion, N/V and alopecia, mainly stage Ⅰ-Ⅱ (WHO criteria) and was reversible. Hematuria was only occasionally encountered with MESNA used concurren-tly.更多还原